Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL538161 | 0.95 | — | — | |
| Water SCHEMBL2064861 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL6508564 | 0.84 | — | — | |
| SCHEMBL10716303 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL28193877 | 0.78 | — | — | |
| Hydrochloric Acid SCHEMBL5846270 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL14894731 | 0.73 | — | — | |
| SCHEMBL28193330 | 0.72 | — | — | |
| SCHEMBL8901756 | 0.72 | — | — | |
| Dimethylamine SCHEMBL10821635 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3409681-B1 | N,N-BIS(2-DIALKYLPHOSPHINOETHYL)AMINE-BORANE COMPLEX AND PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING RUTHENIUM COMPLEX CONTAINING N,N-BIS(2-DIALKYLPHOSPHINOETHYL)AMINE AS LIGAND | TAKASAGO PERFUMERY CO LTD (JP) | 2020-09-16 | — | — | EP | disclosed |
| US-10407448-B2 | N-N-bis(2-dialkylphosphinoethyl)amine-borane complex and production method therefor, and method for producing ruthenium complex containing N,N-bis(2-dialkylphosphinoethyl)amine as ligand | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-09-10 | — | — | US | disclosed |
| US-10203334-B2 | Methods and compositions related to nucleic acid binding assays | Nubad, LLC (US) | 2019-02-12 | — | — | US | disclosed |
| US-20190040090-A1 | N,N-BIS(2-DIALKYLPHOSPHINOETHYL)AMINE-BORANE COMPLEX AND PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING RUTHENIUM COMPLEX CONTAINING N,N-BIS(2-DIALKYLPHOSPHINOETHYL)AMINE AS LIGAND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2019-02-07 | — | — | US | disclosed |
| EP-3409681-A1 | N,N-BIS(2-DIALKYLPHOSPHINOETHYL)AMINE-BORANE COMPLEX AND PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING RUTHENIUM COMPLEX CONTAINING N,N-BIS(2-DIALKYLPHOSPHINOETHYL)AMINE AS LIGAND | Takasago International Corporation (JP) | 2018-12-05 | — | — | EP | disclosed |
| US-10072033-B2 | N-(phosphinoalkyl)-N-(thioalkyl)amine derivative, method for producing same, and metal complex thereof | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20170233418-A1 | N-(PHOSPHINOALKYL)-N-(THIOALKYL)AMINE DERIVATIVE, METHOD FOR PRODUCING SAME, AND METAL COMPLEX THEREOF | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
| US-20160282357-A1 | METHODS AND COMPOSITIONS RELATED TO NUCLEIC ACID BINDING ASSAYS | Nubad, LLC | 2016-09-29 | — | — | US | disclosed |
| US-9410186-B2 | Methods and compositions related to nucleic acid binding assays | NUBAD LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9017943-B2 | Methods and compositions related to nucleic acid binding assays | NUBAD LLC (US) | 2015-04-28 | — | — | US | disclosed |
| US-5859014-A | USEFUL IN TREATMENT OF DISEASES INVOLVING DIRECTLY OR INDIRECTLY AN OBSTRUCTION OF THE LOWER URINARY TRACT, SUCH ASBENIGN PROSTATE HYPERPLASIA | SYNTEX (U.S.A.) INC. (US) | 1999-01-12 | — | — | US | disclosed |
| US-5688795-A | URINARY TRACTS OBSTRUCTION | SYNTEX (U.S.A.) INC. (US) | 1997-11-18 | — | — | US | disclosed |
| EP-0748800-A2 | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1996-12-18 | — | — | EP | disclosed |
| EP-0711757-A1 | 3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy -pyridine, pyrimidine and benzene derivatives as alpha1-adrenoceptor antagonists | F. Hoffmann-La Roche AG (CH) | 1996-05-15 | — | — | EP | disclosed |
| US-5166157-A | Analgesics, antidepressants or psychological disorders | ADIR ET COMPAGNIE (FR) | 1992-11-24 | — | — | US | disclosed |
| US-5166156-A | Headaches, schizophrenia; stress relieving; analgesics, anxiolytics, antidepressants; hypotensive agents | ADIR ET COMPAGNIE (FR) | 1992-11-24 | — | — | US | disclosed |
| US-5162324-A | Naphyl piperazines useful as 5-HT1A receptor ligands | ADIR ET COMPAGNIE (FR) | 1992-11-10 | — | — | US | disclosed |
| US-5162321-A | 1-naphthyl piperazines useful as 5-HT1A receptor ligands | ADIR ET COMPAGNIE (FR) | 1992-11-10 | — | — | US | disclosed |
| US-5143916-A | Hypotensive agents | ADIR ET COMPAGNIE (FR) | 1992-09-01 | — | — | US | disclosed |
| US-4950670-A | Psychological and cardiovascular disorders | SYNTHELABO (FR) | 1990-08-21 | — | — | US | disclosed |